Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2/Phase 3
INTerpath-007
A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)
- NCT06295809 ↗
- Terminated
- Merck Sharp & Dohme LLC
- Focused
We haven't built an HCP commentary report on INTerpath-007 (pembrolizumab and intismeran autogene in Carcinoma, Squamous Cell) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on INTerpath-007 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2/3, Adaptive, Randomized, Open-label, Clinical Study to Evaluate Neoadjuvant and Adjuvant Intismeran Autogene (mRNA-4157) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care, and Pembrolizumab Monotherapy in Participants With Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (INTerpath-007)
- Phase
- Phase 2/Phase 3
- Status
- Terminated
- Conditions
- Carcinoma, Squamous Cell; Skin Neoplasms
- Interventions
- Pembrolizumab; Intismeran autogene; Surgery
- Arms
- Pembrolizumab plus Intismeran autogene with SOC · Experimental
- Standard of Care (SOC) · Active comparator
- Pembrolizumab with SOC · Experimental
- Enrollment
- 46
- Primary outcomes
- Event Free Survival (EFS)
- Sponsor
- Merck Sharp & Dohme LLC with ModernaTX, Inc.
- Start
- Apr 18, 2024
- Primary completion
- Mar 5, 2026
- Results posted
- No
- Registry record
- NCT06295809 · updated May 8, 2026